

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT – ENTERED INTO A LICENSING AGREEMENT IN RELATION TO THE MARKETING REGISTRATION AND COMMERCIALIZATION OF STAPOKIBART INJECTION IN 18 COUNTRIES AND REGIONS INCLUDING SOUTHEAST ASIA AND CENTRAL ASIA

This announcement is made by Keymed Biosciences Inc. (the “**Company**” or “**Keymed**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

Keymed entered into an exclusive licensing agreement with multinational pharmaceutical company Aeira Pte. Ltd. (“**Aeira**”). Both parties will collaborate on the marketing registration and commercialization of the IL-4R α -targeted monoclonal antibody independently developed by Keymed, Stapokibart injection (trade name: Kangyueda[®]), in Southeast Asia and Central Asia.

Pursuant to the agreement, Keymed will receive an upfront payment, as well as milestone payments upon the approval of marketing applications in various countries and commercialization milestone payments, and is entitled to receive royalties of up to a high double-digit percentage based on the net sales of the product in the licensed territory.

Aeira will be responsible for the registration filings and commercialization matters of Stapokibart injection in a total of 18 countries and regions, including 11 countries in the Southeast Asia region (Brunei Darussalam, Cambodia, Indonesia, Lao People’s Democratic Republic, Malaysia, Myanmar, the Philippines, Singapore, Thailand, Timor-Leste and Vietnam) and 5 countries in the Central Asia region (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan), as well as the Hong Kong Special Administrative Region and the Macao Special Administrative Region. Keymed will continue to be responsible for the manufacture and product supply of Stapokibart injection for Aeira.

This collaboration represents an important milestone in the internationalization strategy for innovative biological drugs of Keymed. Leveraging the partner’s unique commercial network and registration experience in Southeast Asia, Central Asia and other regions, it will accelerate the launch and commercialization process of Stapokibart in the aforementioned regions, further enhancing the global accessibility of the Company’s innovative products and benefiting more patients.

ABOUT STAPOKIBART

Stapokibart (trade name: Kangyueda®, R&D codename: CM310) is a high-efficient, humanized antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα), and is the first domestically manufactured IL-4Rα antibody drug granted marketing approval by the NMPA. By targeting IL-4Rα, Stapokibart can block both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. IL-4 and IL-13 are two key cytokines that trigger type II inflammation. Stapokibart has demonstrated good safety and encouraging efficacy in multiple previous clinical trials, and its treatment of the indication of moderate-to-severe atopic dermatitis in adults, the indication of chronic rhinosinusitis with nasal polyposis and the indication of seasonal allergic rhinitis have been approved for marketing in September 2024, December 2024 and February 2025, respectively.

RISK WARNING

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company and its collaborators will ultimately succeed in developing, listing and/or commercializing Stapokibart in Southeast Asia, Central Asia, the Hong Kong Special Administrative Region and the Macao Special Administrative Region. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, September 2, 2026

As at the date of this announcement, the Board of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; and Prof. Xiao-Fan WANG, Prof. Yang KE and Mr. Cheuk Kin Stephen LAW as independent non-executive Directors.